15 completed, 3 unknown, 1 suspended. 19 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 15, Unknown 3, Suspended 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Unknown 2 |
Follow Heartburn: new trials by email Literature Review of Heartburn trials Research Report on Heartburn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD MHS-1031, Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Microbiome Health Sciences | 255 | 2023-03-03 | 2026-07-27 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Vonoprazan, Placebo - Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn | Phase 2 | Completed | Phathom Pharmaceuticals, Inc. | 458 | 2021-03-25 | 2023-01-04 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy TDF tablet, Entecavir Tablet, QL-007 - Chronic Hepatitis b | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 60 | 2019-07-26 | 2019-11-08 |
| Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation Cochlear Implantation, Cochlear Implantation+dexamethasone, Cochlear Implantation+dexamethasone+hyaluronic acid - Hearing Loss | Phase 2 | Completed | University of Sao Paulo General Hospital | 18 | 2011-11-01 | 2014-10-03 |
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial Fluoxetine, Omeprazole, placebo - Non-erosive Reflux Disease | Phase 2 / Phase 3 | Completed | Tehran University of Medical Sciences | 144 | 2010-08-01 | 2012-03-06 |
| Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE. Secretol, Nexium - Gastroesophageal Reflux Disease (GERD), Heartburn | Phase 1 / Phase 2 | Unknown | Effexus Pharmaceutical | 40 | 2010-05-01 | 2014-08-05 |
| Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide - Heartburn | Phase 2 | Completed | Novartis | 120 | 2009-12-01 | 2011-03-28 |
| Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms VECAM 40/300, Esomeprazole 20 mg - Gastroesophageal Reflux | Phase 2 | Completed | Vecta Ltd. | 52 | 2009-12-01 | 2012-07-30 |
| Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI lesogaberan (AZD3355), Placebo - Gastroesophageal Reflux Disease, Heartburn | Phase 2 | Completed | AstraZeneca | 661 | 2009-10-01 | 2011-04-25 |
| ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) ADX10059, ADX10059 Matching Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Addex Pharma S.A. | 120 | 2008-12-01 | 2009-12-24 |
| ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) ADX10059, ADX10059 Matching Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Addex Pharma S.A. | 298 | 2008-12-01 | 2012-07-16 |
| Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms AZD3355, Placebo, Gelusil® - GERD, Acid Reflux Disease | Phase 2 | Completed | AstraZeneca | 478 | 2008-05-01 | 2011-06-20 |
| Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD. Pantoprazole, placebo - Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | Southern Arizona VA Health Care System | 40 | 2008-04-01 | 2010-08-19 |
| Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis Ilaprazole, Lansoprazole - Esophagitis | Phase 2 | Completed | Takeda | 831 | 2007-05-01 | 2012-02-02 |
| Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients AZD3355 - Gastroesophageal Reflux Disease (GERD) | Phase 2 | Completed | AstraZeneca | 244 | 2006-11-01 | 2013-03-18 |
| Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant - Gastroesophageal Reflux Disease | Phase 2 / Phase 3 | Completed | US Department of Veterans Affairs | 236 | 2006-04-01 | 2014-08-18 |
| Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis S-Tenatoprazole-Na (STU-Na) - Esophagitis, Reflux | Phase 2 | Suspended | STEBA France | 450 | 2006-02-01 | 2008-03-19 |
| A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD) Tegaserod - Symptomatic Gastroespohageal Reflux Disease | Phase 2 | Completed | Novartis | 832 | 2004-01-01 | 2010-09-01 |
Gastroesophageal Reflux (12) · Esophagitis (3) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1) · Depression (1) · Dyspepsia (1) · Esophagitis, Peptic (1) · Glomerulonephritis (1) · Guillain-Barre Syndrome (1) · Hearing Loss (1)
Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (19) · Signs and Symptoms, Digestive (19) · Digestive System Diseases (16) · Esophageal Diseases (15) · Gastrointestinal Diseases (15) · Deglutition Disorders (13) · Esophageal Motility Disorders (13) · Gastroenteritis (4) · Neurologic Manifestations (3) · Chronic Disease (2) · Disease Attributes (2) · Liver Diseases (2) · Nervous System Diseases (2) · Pathologic Processes (2)
Lansoprazole (3) · lesogaberan (3) · Esomeprazole (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Calcium Carbonate (1) · Cochlear Implantation (1) · Dexamethasone (1) · Fluoxetine (1) · Gelusil (1) · Hyaluronic Acid (1) · Magnesium Hydroxide (1) · Nortriptyline (1) · Omeprazole (1) · Pantoprazole (1) · Rabeprazole (1)
AstraZeneca (3) · Addex Pharma S.A. (2) · Novartis (2) · All Natural Medicine Clinic, LLC (1) · Effexus Pharmaceutical (1) · Microbiome Health Sciences (1) · Phathom Pharmaceuticals, Inc. (1) · Qilu Pharmaceutical Co., Ltd. (1) · STEBA France (1) · Southern Arizona VA Health Care System (1) · Takeda (1) · Tehran University of Medical Sciences (1) · US Department of Veterans Affairs (1) · University of Sao Paulo General Hospital (1) · Vecta Ltd. (1)
United States (13) · France (3) · Germany (3) · Belgium (2) · Netherlands (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · China (1) · Hungary (1) · Iran (1) · Norway (1) · Romania (1) · Switzerland (1)
Debra Silberg, MD (2) · Ronnie Fass, MD (2) · Akbar Fotouhi, MD, PhD (1) · Alan Thomson, MD, Prof. (1) · Arash Etemadi, MD, PhD (1) · Behtash Saeidi, MD (1) · Bernardo F Ramos (1) · Guy Boeckxstaens, MD (1) · Jinlin Hou, PhD (1) · Junqi Niu, PhD (1) · Kaveh Hajifathalian, MD (1) · Mohammad Reza Ostovaneh, MD,MPH (1) · Nicholas Shaheen, MD, MPH (1)
PMID 21320138, PMID 21402616, PMID 22730470, PMID 23318482, PMID 23919738, PMID 24533896, PMID 25304129, PMID 27712711, PMID 37750406
2008 (2)